



**LV Diastolic Function (LVDF)
In the Young and Old**

- Introduction
- How does age affect LVDF?
- When does LVDF become abnormal?
Transition to HFPEF?
- Can we prevent LVDD?

LV Diastolic Dysfunction (LVDD)

- Abnormality of LV relaxation, distensibility and filling irrespective of LVEF or symptoms
- Propensity of LV to develop \uparrow filling pressure (LVFP or LVEDP)
- LVFP \neq LVDD
 \neq LAP or PCWP

Assessing LVDF

- Active LV relaxation: Analysis of pressure decline (tau)
- Passive LV filling/chamber stiffness (effective operating compliance): Analysis of pressure-volume curves (stiffness constant)

LVDF Assessment by Echo


	Normal	Abnormal Relaxation (Grade 1)	Pseudo-normal (Grade 2)	Restrictive (Grade 3-4)
ECG				
Mitral Inflow				
Pulm Veins				
Tissue Doppler				
Color M-mode				


Διαστολή (Diastolé)


LV relaxation	+++	++	+	—
LV elastic recoil	+++	+++	—	—
LV compliance	—	++	++	+++
LA pressure	—	+++	++	++


LVDF by Echo: "Post-Truth"?


- Indicates \uparrow LVFP, not myocardial abnormality or LVEDPVR: E, E/A
- Load dependence: nearly all pseudonormalize
- Composite indexes \uparrow measurement error: E/e'




















2016 ASE Diastolic Function Guidelines

Table 4 LV relaxation, filling pressures and 2D and Doppler findings according to LV diastolic function


	Normal	Grade I	Grade II	Grade III
LV relaxation	Normal	Impaired	Impaired	Impaired
LAP	Normal	Low or normal	Elevated	Elevated
Mitral E/A ratio	≥ 0.8	≤ 0.8	>0.8 to <2	>2
Average E/e' ratio	<10	<10	10–14	>14
Peak TR velocity (m/sec)	<2.8	<2.8	>2.8	>2.8
LA volume index	Normal	Normal or increased	Increased	Increased

2016 ASE Guidelines: Caveats

- Expert consensus, not fully validated
- Confusion as to which algorithm to use
- Indexes often provide conflicting “indeterminate” info
- Not pure diastolic index: LAVI, PASP
- Affected by non-diastolic factors: PASP, LAVI
- Not routinely applicable in many situations: AF, VHD, etc

Pitfalls of e' and E/e'


- E/e' derived from empiric observations
- Unreliable in
 - Spherical LV, hyperdynamic state
 - RWMA: AMI/scar, paced, LBBB
 - MV disease: MS, MR > moderate, MVR/repair
 - MAC, Constriction
 - Others: LVAD, RV disease (lateral vs. septal e')
- Measurement error




Hummel. Eur J Heart Fail. 2017

Left Atrial Volume

- LA enlargement is not index of instantaneous pressure
 - takes time to occur
 - persists long after LAP ↓
- LAE may be present in
 - athletes
 - bradycardia
 - anemia
 - atrial arrhythmias
 - MV disease




Pulmonary Vein Doppler





Mean LAP high if
 • S/D ratio <1
 • systolic filling fraction <40%


Rossvoll and Hatle. J Am Coll Cardiol 1993

49/M, Amyloid Heart















Table 1. Left Ventricular Pressure, Volume, Relaxation, and Passive Stiffness.*


Variable	Patients with Diastolic Heart Failure (N=47)	Controls (N=10)	P Value
Body-surface area (m ²)	2.2±0.25	2.1±0.18	0.31
Heart rate (beats/min)	71±11	73±13	0.81
Volume at P _{min} (ml)	51±13	55±7	0.31
Volume at P _{max} (ml)	75±15	88±8	0.03
End-diastolic volume (ml)	103±22	115±9	0.01
P _{min} (mm Hg)	12±6	4±1	<0.001
P _{max} (mm Hg)	16±5	6±2	<0.001
End-diastolic pressure (mm Hg)	25±6	8±2	<0.001
τ (msec)	59±14	35±10	0.01
P _{1/2} (mm Hg)	7±5	0	<0.001
Corrected minimal diastolic pressure (mm Hg)	5±2	4±1	0.10
Measured stiffness			
Curve-fitting constant	6.5±4.3	2.3±0.8	0.003
Stiffness constant	0.02±0.01	0.01±0.01	0.01
Corrected stiffness			
Curve-fitting constant	1.5±1.1	2.3±0.8	0.03
Stiffness constant	0.03±0.01	0.01±0.01	<0.001


Zile, N Engl J Med 2004;350:1953-9


















Background. Heart failure with preserved ejection fraction (HFpEF), traditionally considered a disease of the elderly, may also affect younger patients. However, little is known about HFpEF in the young.

Methods. We prospectively enrolled 1203 patients with HFpEF (LVEF \geq 50%) from 11 Asian regions. We grouped patients into very young (<55 years; N=157), young (55-64 years; N=284), older (65-74 years; N=355), and elderly (\geq 75 years; N=407) HFpEF, and compared clinical and echocardiographic characteristics, quality of life and outcomes across age groups and between very young HFpEF and age- and sex-matched controls without HF.

Results. Thirty seven percent (37%) of our HFpEF population was under 65 years of age. Younger age was associated with male preponderance, a higher prevalence of obesity (BMI \geq 30 kg/m 2 ; 36% in very young HFpEF vs 16% in elderly) together with less renal impairment, atrial fibrillation and hypertension (all p<0.001). Left ventricular filling pressures and prevalence of LV hypertrophy were similar in very young and elderly HFpEF. Quality of life was better, and death and HF hospitalization at 1 year occurred less frequently (p=0.001) in the very young (7%) compared to elderly (21%) HFpEF. Compared to controls, very young HFpEF had three-fold higher death rate and twice the prevalence of hypertrophy.

Conclusion. Young and very young patients with HFpEF display similar adverse cardiac remodeling as their older counterparts, and very poor outcomes compared to controls without HF. Obesity may be a major driver of HFpEF in a high proportion of HFpEF in the young and very young.



Conclusions

- LVDF is a continuum, with evolution from early age
- Despite authoritative guidelines, distinction between normal and abnormal LVDF is often unclear
- Pitfalls and limitations of LVDF indexes should be recognized; newer ones e.g. PALS may be useful in resolving "indeterminate" LVDF
- Prevention of LVDD seems possible by risk factor intervention but needs verification in larger studies.
